EGFR-CD3 Bispecific Probody™ Therapeutic Induces Tumor Regressions and Increases Maximum Tolerated Dose > 60 fold in Preclinical Studies

Leila M. Boustany, Sherry L. La Porte, Laurie Wong, Clayton W. White, Linnea Diep, Yuanhui Huang, Shouchun Liu, Jennifer H. Richardson, W. Michael Kavanaugh, Bryan A. Irving. Poster presented at AACR-NCI-EORTC International Conference on Molecular Targets 2017, October 26-30, Philadelphia, Pennsylvania.